Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 17/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650068 | 0.84 | KMT2A (0.51) | ALDH1A1POLBMAPT | |
| SCHEMBL27826145 | 0.84 | TRPM8 (0.46) | L3MBTL1 | |
| SCHEMBL4358333 | 0.83 | PPARD (0.42) | PPARDALDH1A1POLBMAPTRECQL | |
| SCHEMBL5652505 | 0.81 | KMT2A (0.40) | ALDH1A1L3MBTL1 | |
| SCHEMBL2246642 | 0.81 | MMP12 (0.41) | ALDH1A1MAPT | |
| SCHEMBL4369489 | 0.80 | PTGES (0.45) | ALDH1A1MAPT | |
| SCHEMBL4367868 | 0.79 | TSHR (0.43) | L3MBTL1 | |
| SCHEMBL5653131 | 0.78 | CYP1A2 (0.46) | MAPTL3MBTL1 | |
| SCHEMBL4621079 | 0.78 | SLC9A1 (0.42) | ALDH1A1POLBMAPT | |
| SCHEMBL2246723 | 0.78 | MMP12 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | PPARD 3286/4885PPARA 3818/4885PSMB5 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.